Team: Global Patient Safety
Location: Bangalore, Novo Nordisk Global Business Services (GBS), India
As Principal Specialist, PV Process Excellence, you will strengthen the governance and continuous improvement of Novo Nordisk's global pharmacovigilance processes. You will translate emerging regulatory requirements into sustainable, compliant and inspection-ready ways of working, and help keep our patient safety system effective at scale. Your work supports the integrity of the system that protects people who rely on our medicines every day.
We are looking for a structured, detail-oriented professional who thrives in a complex, global environment and is motivated by continuous improvement. To succeed, you bring:
You will drive strategic governance and continuous improvement across one or more Process Excellence areas, working alongside content owners and functional stake-holders to keep processes mature and inspection-ready. Day to day, you will:
You will join the QPPV Office team within Global Patient Safety (GPS) in Research & Development – the team re-sponsible for the integrity, quality and compliance of our global pharmacovigilance system. In R&D, colleagues explore bold scientific ideas and advance them into clinical testing, combining curiosity, data and technology to meet future patient needs.
You will work closely with the Director, PV Process Excellence, the EU QPPV and Deputy QPPVs, and Global Patient Safety leadership. Your wider network spans GPS departments, our Global Business Services centre in Bangalore, Novo Nordisk affiliates, R&D, health authorities and contractual partners across the globe – bringing the right expertise together to keep the system compliant and moving forward.
You will work in a global environment where your expertise shapes how our pharmacovigilance system operates and where you are trusted to take ownership and speak up. The role offers the chance to build new skills through cross-functional collaboration, grow alongside experienced colleagues, and be supported to perform at your best while contributing to a shared standard of quality and compliance.
Your impact begins today. If you are ready to strengthen the governance and continuous improvement of our global pharmacovigilance system, apply for the Principal Specialist, PV Process Excellence role by 7 October 2026. Applications are reviewed on an ongoing basis, so we encourage you to apply as soon as possible.
We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html